EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

Kohei Shitara iD, Eric Van Cutsem, Mahmut Gümüş, Sara Lonardi, Christelle de la Fouchardière, Clélia Coutzac, Jeroen Dekervel, Daniel Hochhauser, Lin Shen, Wasat Mansoor, Bo Liu, Lorenzo Fornaro und 14 weitere

New England Journal of Medicine · 24.07.2025 · 393 (4) · 336-348

DOI: 10.1056/nejmoa2503119 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 24.07.2025. Verfasst von Kohei Shitara und 25 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Ramucirumab. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsRamucirumabStomach NeoplasmsTrastuzumabAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedEsophagogastric JunctionImmunoconjugatesKaplan-Meier EstimatePaclitaxelProgression-Free SurvivalErb-b2 Receptor Tyrosine KinasesBiopsyPathologic Complete ResponseLung Diseases, InterstitialPneumoniaYoung AdultCamptothecin

Substanzen

Antibodies, Monoclonal, HumanizedImmunoconjugatesPaclitaxelRamucirumabErb-b2 Receptor Tyrosine KinasesTrastuzumabCamptothecintrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Kashiwa, Japan.
  • University Hospitals Gasthuisberg, Leuven, Belgium.
  • University of Leuven, Leuven, Belgium.
  • Istanbul Medeniyet University, Istanbul, Turkey.
  • Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey.
  • Veneto Institute of Oncology IRCCS, Padua, Italy.

ORCID-Profile: Kohei Shitara

Zitieren

APA

Shitara, K., Van Cutsem, E., Gümüş, M., Lonardi, S., de la Fouchardière, C., Coutzac, C., Dekervel, J., Hochhauser, D., Shen, L., Mansoor, W., Liu, B., Fornaro, L., Ryu, M. H., Lee, J., Faustino, C., Metges, J. P., Tabernero, J., Franke, F., Janjigian, Y. Y., …, & DESTINY-Gastric04 Trial Investigators (2025). Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. New England Journal of Medicine, 393(4), 336-348. https://doi.org/10.1056/nejmoa2503119

Vancouver

Shitara K, Van Cutsem E, Gümüş M, Lonardi S, de la Fouchardière C, Coutzac C, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. New England Journal of Medicine. 2025;393(4):336-348. doi:10.1056/nejmoa2503119

BibTeX
@article{Shitara2025,
  author = {Shitara, Kohei and Van Cutsem, Eric and Gümüş, Mahmut and Lonardi, Sara and de la Fouchardière, Christelle and Coutzac, Clélia and Dekervel, Jeroen and Hochhauser, Daniel and Shen, Lin and Mansoor, Wasat and Liu, Bo and Fornaro, Lorenzo and Ryu, Min-Hee and Lee, Jeeyun and Faustino, Cátia and Metges, Jean-Philippe and Tabernero, Josep and Franke, Fábio and Janjigian, Yelena Y and Souza, Fabricio and Jukofsky, Lori and Zhao, Yumin and Kamio, Takahiro and Zaanan, Aziz and Pietrantonio, Filippo and DESTINY-Gastric04 Trial Investigators, DESTINY-Gastric04 Trial Investigators},
  title = {Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {4},
  pages = {336--348},
  doi = {10.1056/nejmoa2503119}
}
Kostenlos starten →